Scholar Rock
SRRKScholar Rock is a clinical-stage biopharmaceutical company specializing in the discovery and development of monoclonal antibodies that target the precursor, or latent, forms of growth factors.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Scholar Rock is a clinical-stage biopharmaceutical company specializing in the discovery and development of monoclonal antibodies that target the precursor, or latent, forms of growth factors. The company leverages a proprietary platform to selectively inhibit the transforming growth factor beta (TGFβ) superfamily, primarily focusing on myostatin to treat rare, severe neuromuscular diseases. Its core value proposition lies in its ability to provide highly selective muscle-targeted therapies that avoid the systemic side effects associated with traditional growth factor inhibition.
A leader in TGFβ superfamily biology with a first-in-class muscle-targeted therapy candidate for SMA that has demonstrated clinical proof-of-concept.
Questions, answered.
- What is Scholar Rock's market cap?
- Scholar Rock (SRRK) has a market capitalization of $5.9B and trades on NASDAQ.
- What is Scholar Rock's revenue and profitability?
- Scholar Rock generated $33.2M in trailing twelve-month revenue with a net loss of $408.7M, representing a net margin of -236.9%, with free cash flow of -$303.9M. These figures are based on the Q1 2026 filing.
- Who are Scholar Rock's competitors?
- Scholar Rock's key competitors include Biogen Inc., Solid Biosciences Inc. Common Stock, Edgewise Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Scholar Rock partner with?
- Scholar Rock's notable partners include Harvard Medical School, Boston Children’s Hospital.
- Where is Scholar Rock headquartered?
- Scholar Rock is headquartered in United States of America and employs approximately 150 people. It has been publicly traded since 2018.
